|
| Authors | Study object | Study design | Size of perforation | Follow-up (months) | Treatment strategy | Closure rate | Mean closure time (days) |
| FGF2 group | Control group | FGF2 group | Control group | FGF2 group | Control group |
|
| Lou et al. [31] (2011) | Children | Retrospective control study | | 6 | FGF2 via GF | SH | 98.5% (64/65) | 85.3% (58/68) | | |
| Lou [32] (2012) | Adult | Randomized, controlled trial | ≥50% of TM | 6 | FGF2 alone or via GF | SH | 100% (32/32) and 97% (32/33) | 55% (16/29) | and | |
| Zhang and Lou [33] (2012) | Adult penetrating | Prospective controlled study | <25% of TM | 3 | FGF2 alone | SH | 100% (49/49) | 77% (34/44) | | |
| Lou and Wang [34] (2013) | Adult | Prospective, controlled study. | >50% of TM | 6 | FGF2 alone | SH and EA | 100% (20/20) | 56% (9/16) and 60% (12/20) | | and |
| Lou et al. [35] (2015) | Adult-blast induced | Prospective clinical study | >75% of TM | 6 | FGF2 alone | | 94.1%(16/17) | | | |
| Lou et al. [36] (2016) | Adult subacute | Prospective control study | 1/8–1/2 of TM | 6 | FGF2 alone | SH | 11/12 (91.7%) | 9/17 (52.9%) | | |
| Lou et al. [37] (2016) | Adult | Prospective controlled study. | >25% of TM | 6 | FGF2 alone | GF and OFLX alone | 93.2% (68/73) | 85.7% (24/28) and 92.3% (36/39) | | and |
| Lou et al. [38] (2016) | Adults | Prospective clinical study. | >25% of TM | 3 | FGF2 alone | EGF alone and SH | 89.3% (25/28) | 86.2% (25/29) and 72.4% (21/29) | | and |
| Lou Z and Lou Z [39] (2017) | Adults | Randomized, controlled trial. | >25% of TM | 6 | FGF2 alone | EGF alone and OFLX alone | 93.18% (41/44) | 91.11% (41/45) and 95.65%(44/46) | 10 | 12 and 10 |
| Jin et al. [40] (2017) | Adults | Prospective, randomized, controlled clinical study. | >25% of TM | 6 | FGF2 via GF | GF vs. SH | 97.9% | 89.8% vs. 70.7% | | vs. days |
| Lou ZC and Lou ZH [41] (2018) | Adult | Randomized, controlled trial | >25% of TM | 12 | FGF2 | SH | 95.5% | 73.4% | | |
| Lou et al. [42] (2016) | Adult | Prospective, randomized clinical trial | ≥1/8 of TM | 6 months | 0.1–0.15 mL of EGF | SH | 91.4% (32/35) | 85.2% (29/34) | | |
| Yang et al. [43] (2016) | Adult | Retrospective case review | ≥25% of TM | 6 months | 0.1–0.15 mL of EGF | 0.1–0.15 mL of OFLX and SH | 93.5% (29/31) | 93.2% (41/44) and 82.2% (37/45) | | and |
| Lou ZC and Lou Z [44] (2018) | Adult | Prospective, randomized, controlled | ≥50% of TM | 6 months | 0.1–0.15 mL of EGF | Gelatin patch and SH | 97.8% | 86.7% and 82.2% | | and |
| Lou et al. [45] (2019) | Adult subacute | Prospective study | ≥1/8 of TM | 6 months | 0.1–0.15 mL of EGF | SH | 96.2% | 61.1% | | |
| Lou [46] (2019) | Adult chronic traumatic | Case observation study | | 6 months | 0.1–0.15 mL of EGF | | 100% (24/24) | | days | |
|
